3 Biotech and Genomics Stocks Riding India’s Life Sciences Growth
- July 17, 2026
- Posted by: Kashish Aggarwal
- Category: News
Biocon, Syngene International and Mankind Pharma continue capturing India’s growing biotech, contract research and specialty pharma investment.
Biocon, Syngene International and Mankind Pharma are among the biotech and genomics stocks riding India’s life sciences growth, each positioned within India’s biotechnology and life sciences manufacturing growth story through distinct business drivers.
India’s biotechnology and life sciences manufacturing sector continues to see sustained investment and demand growth, and biotech and genomics stocks riding India’s life sciences growth reflects companies with the clearest exposure to this trend.
Click Here – Get Free Investment Predictions
This article examines Biocon, Syngene International and Mankind Pharma as biotech and genomics stocks riding India’s life sciences growth, covering their specific growth drivers and the risks of this theme.
What Defines the 3 Biotech and Genomics Stocks Riding India’s Life Sciences Growth
The biotech and genomics stocks riding India’s life sciences growth are companies with direct exposure to biotechnology and life sciences manufacturing, combining relevant scale with disclosed growth or expansion plans.
Understanding these biotech and genomics stocks riding India’s life sciences growth helps investors identify names positioned to benefit from sustained sector-wide demand rather than one-off catalysts.
Why These Are the 3 Biotech and Genomics Stocks Riding India’s Life Sciences Growth
Biocon’s biosimilars and biologics manufacturing leadership, Syngene International’s contract research and manufacturing services scale and Mankind Pharma’s domestic formulations leadership with consumer healthcare diversification together explain why these represent the biotech and genomics stocks riding India’s life sciences growth.
- Biocon’s biosimilars and biologics manufacturing leadership: Biocon’s its biosimilars and biologics manufacturing leadership, maintaining a strong global pipeline of complex biological drug products.
- Syngene International’s contract research and manufacturing services scale: Syngene International’s its contract research and manufacturing services scale, supporting global pharmaceutical and biotech clients with outsourced R&D and manufacturing capacity.
- Mankind Pharma’s domestic formulations leadership with consumer healthcare diversification: Mankind Pharma’s its domestic formulations leadership combined with consumer healthcare diversification, spanning both prescription and over-the-counter product categories.
- Sustained sector-wide demand: Broader structural demand growth across biotechnology and life sciences manufacturing supports all three companies within this theme.
| Company | CMP (Rs) | Growth Driver | Sector |
|---|---|---|---|
| Biocon | – | Biosimilars and biologics manufacturing leadership | Biotechnology |
| Syngene International | – | Contract research and manufacturing services scale | Biotechnology |
| Mankind Pharma | – | Domestic formulations leadership with consumer healthcare diversification | Biotechnology |
Biocon: Biosimilars and biologics manufacturing leadership
Biocon is among the biotech and genomics stocks riding India’s life sciences growth, its biosimilars and biologics manufacturing leadership, maintaining a strong global pipeline of complex biological drug products.
The company’s early investment in biosimilar development has positioned it as one of India’s leading biologics manufacturers for global markets.
Syngene International: Contract research and manufacturing services scale
Syngene International is among the biotech and genomics stocks riding India’s life sciences growth, its contract research and manufacturing services scale, supporting global pharmaceutical and biotech clients with outsourced R&D and manufacturing capacity.
The company’s integrated research-to-manufacturing services model has attracted long-term partnerships with major global pharmaceutical companies.
Get SEBI-Registered Research on Biotech and Genomics Growth Stocks
Mankind Pharma: Domestic formulations leadership with consumer healthcare diversification
Mankind Pharma is among the biotech and genomics stocks riding India’s life sciences growth, its domestic formulations leadership combined with consumer healthcare diversification, spanning both prescription and over-the-counter product categories.
The company’s strong domestic brand recognition and distribution network support sustained market share across multiple therapeutic categories.
Download the Univest iOS App or Univest Android App to track Biocon, Syngene International and Mankind Pharma live prices.
Factors Affecting the 3 Biotech and Genomics Stocks Riding India’s Life Sciences Growth
- Execution track record: For the biotech and genomics stocks riding India’s life sciences growth, execution against disclosed plans remains the key determinant of realised growth.
- Sector-wide demand trends: Broader demand trends across biotechnology and life sciences manufacturing affect all three companies collectively.
- Competitive intensity: Rising competition within biotechnology and life sciences manufacturing could pressure margins even amid volume growth.
- Input cost and supply chain factors: Cost and supply chain dynamics affect profitability for companies within this theme.
- Policy and regulatory support: Government policy support toward biotechnology and life sciences manufacturing affects the sustainability of this growth theme.
Benefits of the 3 Biotech and Genomics Stocks Riding India’s Life Sciences Growth
- Structural growth theme exposure: The biotech and genomics stocks riding India’s life sciences growth provide exposure to a sustained, structural growth theme rather than a short-term cycle.
- Diversified company selection: Spanning three companies, this list reduces single-stock concentration risk within the theme.
- Established execution capability: These companies bring existing scale and expertise to capture growth within biotechnology and life sciences manufacturing.
- Policy-aligned positioning: These stocks align with broader government policy priorities supporting this sector.
- Multiple growth vectors: Different business models across these three names offer diversified ways to capture the same broad theme.
Risks of the 3 Biotech and Genomics Stocks Riding India’s Life Sciences Growth
- Execution risk: These companies still need to execute disclosed plans successfully to realise growth.
- Valuation considerations: Strong recent sector performance means current valuations may already reflect growth expectations for the biotech and genomics stocks riding India’s life sciences growth.
- Competitive pressure: Rising competition within biotechnology and life sciences manufacturing could affect market share and margins over time.
- Cyclicality risk: Demand within biotechnology and life sciences manufacturing could prove more cyclical than currently anticipated.
- Broader market sentiment risk: Overall market conditions can affect these stocks regardless of company-specific fundamentals.
How to Evaluate the 3 Biotech and Genomics Stocks Riding India’s Life Sciences Growth
- Among the biotech and genomics stocks riding India’s life sciences growth, compare execution track record against disclosed growth and expansion plans.
- For the biotech and genomics stocks riding India’s life sciences growth, assess competitive positioning within the broader biotechnology and life sciences manufacturing sector.
- Track quarterly results to confirm continued execution progress.
- Consider valuation relative to growth visibility for each name.
- Combine sector-theme analysis with standard fundamental research.
How to Invest in the 3 Biotech and Genomics Stocks Riding India’s Life Sciences Growth
- Use the Univest platform to track quarterly results and expansion progress for the biotech and genomics stocks riding India’s life sciences growth.
- Open a demat and trading account with Univest for zero-brokerage execution.
- Track quarterly results for Biocon, Syngene International and Mankind Pharma through the Univest app.
- Consult a SEBI-registered advisor before allocating capital to this theme.
- Review positions periodically as execution progress and sector trends evolve.
Conclusion
Biocon, Syngene International and Mankind Pharma represent the biotech and genomics stocks riding India’s life sciences growth, each capturing different aspects of India’s sustained biotechnology and life sciences manufacturing growth story. Historically, this structural theme has offered diversified exposure across multiple companies, though execution risk and valuation considerations remain important factors. Consult a SEBI-registered advisor before making investment decisions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs
3 Biotech and Genomics Stocks Riding India’s Life Sciences Growth?
Ans. Biocon, Syngene International and Mankind Pharma are the biotech and genomics stocks riding India’s life sciences growth.
What drives Biocon’s growth in this theme?
Ans. Biocon benefits from biosimilars and biologics manufacturing leadership.
What drives Syngene International’s growth in this theme?
Ans. Syngene International benefits from contract research and manufacturing services scale.
What drives Mankind Pharma’s growth in this theme?
Ans. Mankind Pharma benefits from domestic formulations leadership with consumer healthcare diversification.
Is this theme purely cyclical or structural?
Ans. The biotech and genomics stocks riding India’s life sciences growth represent a structural growth theme, though cyclicality risk remains a consideration.
What risks apply to the 3 Biotech and Genomics Stocks Riding India’s Life Sciences Growth?
Ans. Key risks include execution risk, valuation considerations, and competitive pressure within the sector.
